↓ Skip to main content

A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage…

Overview of attention for article published in Investigational New Drugs, May 2013
Altmetric Badge

Readers on

mendeley
44 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer
Published in
Investigational New Drugs, May 2013
DOI 10.1007/s10637-013-9973-4
Pubmed ID
Authors

K. H. Park, J. H. Sohn, S. Lee, J. H. Park, S. Y. Kang, H. Y. Kim, I. H. Park, Y. H. Park, Y. H. Im, H. J. Lee, D. S. Hong, S. Park, S. H. Shin, H. C. Kwon, J. H. Seo

Abstract

A pegylated form of recombinant granulocyte-colony stimulating factor (G-CSF) was developed for prophylactic use in breast cancer. The aim of this study was to evaluate the efficacy and safety of once-per-cycle DA-3031 in patients receiving chemotherapy for breast cancer.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 2%
Unknown 43 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 18%
Student > Doctoral Student 5 11%
Student > Bachelor 4 9%
Professor 3 7%
Lecturer 3 7%
Other 12 27%
Unknown 9 20%
Readers by discipline Count As %
Medicine and Dentistry 18 41%
Pharmacology, Toxicology and Pharmaceutical Science 4 9%
Psychology 2 5%
Immunology and Microbiology 1 2%
Economics, Econometrics and Finance 1 2%
Other 5 11%
Unknown 13 30%